In draft final guidance, NICE has recommended the use of Jetrea (ocriplasmin) as an option for treating vitreomacular traction in adults, only if an epiretinal membrane is not present, and they have a stage II macular hole (full thickness with a diameter of 400 micrometres or less) and/or they have severe symptoms.
NICE has not yet issued final guidance to the NHS; these decisions may change in the event of an appeal. Until NICE issues final guidance, NHS bodies should make decisions locally on the funding of specific treatments. Once NICE issues its guidance on a technology it replaces local recommendations across the country. Final guidance is expected to be published in October 2013. For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/NICEGivesGreenLightEyeConditionTreatment.jsp